Access Biotechnology led a $300m Series C round in ACELYRIN.

Access Biotechnology, an investment arm of Access Industries that focuses on private and public biopharma companies, led a $300m Series C round in ACELYRIN, a late-stage clinical biopharma company focused on accelerating the delivery of transformative medicines in immunology, with participation from Matrix Capital Management, Westlake Village BioPartners, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, Samsara BioCapital, Surveyor Capital, Tybourne Capital Management, and venBio Partners. "The team at ACELYRIN are world-leading drug developers, having previously brought to millions of patients several of the most successful and impactful immunology treatments available. We are pleased to lead this round of financing to enable their growth in continuing to explore the potential of izokibep in psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, uveitis, and beyond," Dan Becker, Access Biotechnology Managing Director.